A Phase 1 interventional study of SB cells and SB cells in Guided Bone Regeneration, sponsored by Taipei Medical University. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-30.
Sponsored by Taipei Medical University · Phase 1, Interventional, and Treatment
This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.
This is a Phase 1 study to evaluate the safety profile of autologous-derived SB cells to enhance osseointegration of GBR in patients undergoing dental implant surgery.
Enrolled subjects eligible to receive GBR procedure will be sequentially assigned to 1 of 3 treatment cohorts as follows:
Treatment dose 1 group:1×10*5 CD61-Lin- cells /0.25mL DPBS Treatment dose 2 group:1×10*6 CD61-Lin- cells /0.25mL DPBS Treatment dose 3 group:1×10*7 CD61-Lin- cells /0.25mL DPBS
After receiving the autologous SB cells solution mixed with 1 mL bone substitute, each first treated subject at each cohort will be followed up to 4-weeks. After the first subject at each cohort (3 subjects) complete a 4-weeks follow-up period, if investigator and sponsor judge that there is not either a safety concern or a dose-limiting toxicity (DLT) criteria is not met, 2 additional subjects within each cohort will be enrolled. A Data Safety Monitoring Committee will be conveyed after the first 3 treated subjects at each cohort complete undergo the dental implant procedure (12-weeks follow-up after GBR) to evaluate the safety and preliminary efficacy of SB cells administered during a GBR procedure, and will provide recommendations regarding study modification, continuation to enroll next subject(s), cohorts or study termination.
If the committee recommends further subject enrollment, sequential recruitment will continue until subjects for each treatment cohort are enrolled, treated and followed up to 24-weeks after GBR (12-weeks after dental implant) unless there is a safety concern judged by investigator, sponsor, or a dose-limiting toxicity (DLT) criteria is met. Once this situation occurs, the committee will assess the progress and safety data of all subjects enrolled, and will provide recommendations regarding study modification, continuation to enroll next subject in that or other cohorts, or will recommend study termination.
Taipei Medical University is the lead sponsor of 245 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who have inadequate organ function described as below:
1x10\*5 CD61-Lin- cells /0.25mL DPBS
Drug: SB cells
1x10\*6 CD61-Lin- cells /0.25mL DPBS
Drug: SB cells
1x10\*7 CD61-Lin- cells /0.25mL DPBS
Drug: SB cells
1x10\*5 CD61-Lin- cells /0.25mL DPBS
1x10\*6 CD61-Lin- cells /0.25mL DPBS
1x10\*7 CD61-Lin- cells /0.25mL DPBS
Number of participants with adverse events
Time frame: Throughout the study, an average of 1 year
The maximum tolerated dose (MTD) of autologous-derived Small Blood Stem Cells in patients undergoing dental implant surgery.
Time frame: Throughout the study, an average of 1 year
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Medical University